Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment

Neuroscience Letters

Volumn 333, Issue 3, 2002, Pages 183-186

  De Leon, M J ^a,b   Segal, S ^a   Tarshish, C Y ^a   DeSanti, S ^a   Zinkowski, R ^c   Mehta, P D ^d   Convit, A ^a,b   Caraos, C ^a   Rusinek, H ^a   Tsui, W ^a,b   Saint Louis, L A ^a   DeBernardis, J ^c   Kerkman, D ^c   Qadri, F ^a   Gary, A ^a   Lesbre, P ^a   Wisniewski, T ^a   Poirier, J ^e   Davies, P ^f  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c Molecular Geriatrics Corporation   (United States)

^d NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^e DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer disease; Amyloid beta; Cerebrospinal fluid; Longitudinal; Magnetic resonance imaging; Mild cognitive impairment; Tau

Indexed keywords

TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; HUMAN; INSULIN CLEARANCE; LONGITUDINAL STUDY; MALE; PHOSPHORYLATION; PRIORITY JOURNAL; REGULATORY MECHANISM;

AGED; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; REFERENCE VALUES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TAU PROTEINS;

EID: 0037195597     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(02)01038-8     Document Type: Article

References (19)

1. Andreasen N., Minthon L., Clarberg A., Davidsson P., Gottfries J., Vanmechelen E., Vanderstichele H., Winblad B., Blennow K. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology. 53:1999;1488-1494.
2. Arai H., Ishiguro K., Ohna H., Moriyama M., Itoh N., Okamura N., Matsui T., Morikawa Y., Horikawa E., Imahori K. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp. Neurol. 166:2000;201-203.
3. Arai H., Terajima M., Miura M., Higuchi S., Muramatsu T., Matsushita S., Machida N., Nakagawa T., Lee V.M., Trojanowski J.Q., Sasaki H. Effect of genetic risk factors and disease progression on the cerebrospinal fluid tau levels in Alzheimer's disease. JAGS. 45:1997;1228-1231.
4. Blomberg M., Jensen M., Basun H., Lannfelt L., Wahlund L.-O. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotien E allele ε4 during 14 months follow-up. Neurosci. Lett. 214:1996;163-166.
5. Buerger K., Teipel S.J., Zinkowski R., Blennow K., Arai H., Engel R., Hofmann-Kiefer K., Miller C., McCulloch B.S., Ptok U., Heun R., Andreasen N., DeBernardis J., Kerkman D., Moeller H.J., Davies P., Hampel H. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 59:2002;627-629.
6. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12:1975;189-198.
7. Fox N.C., Freeborough P.A. Brain Atrophy Progression Measured from Registered Serial MRI: Validation and Aplication to Alzheimer's Disease. J. Mag. Reson. Imag. 7:1997;1069-1075.
8. Hampel H., Buerger K., Kohnken R., Teipel S.J., Zinkowski R., Moeller H.J., Rapoport S.I., Davies P. Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. Ann. Neurol. 49:2001;545-546.
9. Kanai M., Shizuka M., Urakami K., Matsubara E., Harigaya Y., Okamoto K., Shoji M. Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease. Neurosci. Lett. 267:1999;65-68.
10. Kluger A., Ferris S.H., Golomb J., Mittelman M.S., Reisberg B. Neuropsychological prediction of decline to dementia in nondemented elderly. J. Geriat. Psychiat. Neurol. 12:1999;168-179.
11. Kohnken R., Buerger K., Zinkowski R., Miller C., Kerkman D., DeBernardis J., Shen J., Moller H.J., Davies P., Hampel H. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci. Lett. 2000;187-190.
12. Mehta P.D., Pirttila T., Mehta S.P., Sersen E.A., Aisen P.S., Wisniewski H.M. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch. Neurol. 57:2000;100-105.
13. Morris J.C., Storandt M., Miller P., McKeel D.W., Price J.L., Rubin E.H., Berg L. Mild cognitive impairment represents early-stage Alzheimer disease. Neurology. 58:2001;397-405.
14. Nishimura T., Takeda M., Nakamura Y., Yosbida Y., Arai H., Sasaki H., Shouji M., Hirai S., Khise K., Tanaka K., Hamamoto M., Yamamoto H., Matsubayashi T., Urakami K., Adachi Y., Nakashima K., Toji H., Nakamura S., Yoshida H. Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan. Methods Find. Exp. Clin. Pharmacol. 20:1998;227-235.
15. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin. Chim. Acta. 310:2001;173-186.
16. Reisberg B., Ferris S.H., de Leon M.J., Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am. J. Psychiatry. 139:1982;1136-1139.
17. Sunderland T., Wolozin B., Galasko D., Levy J., Dukoff R., Bahro M., Lasser R., Motter R., Lehtimaki T., Seubert P. Longitudinal stability of CSF tau levels in Alzheimer patients. Biol. Psychiatry. 46:1999;750-755.
18. Tapiola T., Pirttila T., Mikkonen M., Mehta P.D., Alafuzoff I., Koivisto K., Soininen H. Three-year follow-up of cerebrospinal fluid tau B-amyloid 42 and 40 concentrations in Alzheimer's disease. Neurosci. Lett. 280:2000;119-122.
19. Vanmechelen E., Vanderstichele H., Hulstaert F., Andreasen N., Minthon L., Winblad B., Davidsson P., Blennow K. Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders. Mech. Ageing Dev. 122:2001;2005-2011.